Prescribing information can be found here
Why choose Invokana (canagliflozin) - After first line, take a firm line
Invokana Efficacy Icon

Glycaemic Efficacy

Invokana eliminates more blood glucose every day than any other SGLT2i 1-4

This is not a head-to-head study; results from phase 1 studies of urinary glucose excretion in patients with T2DM. 1-4

Invokana gets more patients to target than any other SGLT2i as add-on to metformin

This is not a head-to-head study; figures are taken from respective Summary of Product Characteristics. 1,3-5

58% of patients given Invokana 300mg in addition to metformin achieve the 7% target 4

Invokana is more effective at reducing HbA1c and weight than some other oral T2DM treatments

Please note that weight loss and blood pressure reductions are not licensed indications for Invokana.

Head-to head studies are not available for all drug combinations; network meta-analyses (NMA) allow indirect treatment comparisons to be made.

Methodology: In an independent NMA using a frequentist model, pairwise random-effects were performed to estimate study variance. The aim of this NMA, which reviewed 38 trials involving 23,997 patients, was to assess the comparative safety and efficacy of SGLT2is in treating hyperglycaemia in adults with T2DM. Data was not available for ertugliflozin at the time of analysis.

  1. Reference 10
  2. Sahasrabudhe V, et al. J Clin Pharm. 2017;57(11):1432-1443
  3. Reference 11
  4. Reference 7
  5. Reference 12
  6. Zaccardi F, et al. Diabetes Obes Metab. 2016;18(8):738-94